MeSH tree: G05.360.340.024.340.375.500
The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes, within a cell, a very ...
Feb 6, 2026
0
9
UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, raising hopes that the molecule could become a much-needed new treatment for the deadliest brain cancer. ...
Feb 4, 2026
0
12
An international research team has succeeded in deciphering a key mechanism that controls the growth of pancreatic cancers. The scientists identified a potential central mechanism by which cancer cells protect themselves ...
Jan 22, 2026
0
22
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease. Potential treatments typically target a key mutated oncogene called KRAS. In some cases, PDAC ...
Jan 8, 2026
0
36
Scientists at St. Jude Children's Research Hospital have revealed previously unappreciated roles for the retrotransposon LINE-1 in shaping the cancer genome structure and regulation. Retrotransposons are mobile DNA pieces, ...
Jan 5, 2026
0
9
Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most often in children and young adults. In recent years, CAR-T cell therapy—often referred to as a "living ...
Jan 2, 2026
0
28
The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, new research reveals.
Dec 5, 2025
0
41
Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed alternative to invasive ...
Dec 4, 2025
0
11
Researchers have identified a molecular mechanism that helps explain why growing up in a stimulating environment enhances memory. In contrast, a lack of stimulation can impair it. The team from the Institute for Neurosciences ...
Dec 3, 2025
0
42
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is synergistically enhanced in combination ...
Dec 2, 2025
0
18
